Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?

Abstract excerpt

PARP inhibition is synthetic lethal with defective DNA repair via homologous recombination. Phase I and II clinical trials show that PARP inhibitors are effective at well-tolerated doses and have antitumor activity for BRCA1- and BRCA2-associated cancers. However, not all patients respond equally well and tumors may eventually become resistant. Thus far, the only resistance mechanism that has been found in human...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to CRISPR and Genetic Engineering
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy